0001209191-16-092944.txt : 20160121 0001209191-16-092944.hdr.sgml : 20160121 20160121180514 ACCESSION NUMBER: 0001209191-16-092944 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160119 FILED AS OF DATE: 20160121 DATE AS OF CHANGE: 20160121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROBIN HOWARD W CENTRAL INDEX KEY: 0001206869 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 161354357 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-01-19 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001206869 ROBIN HOWARD W C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 1 1 0 0 President & CEO Common Stock 2016-01-19 4 M 0 66667 6.46 A 76667 D Common Stock 2016-01-19 4 S 0 66667 14.12 D 10000 D Common Stock 410 I by spouse Stock Option 6.46 2016-01-19 4 M 0 66667 0.00 D 2012-02-25 2016-02-24 Common Stock 66667 66666 D This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in early 2016 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16, 2015. This transaction was executed in multiple trades at prices ranging from $13.67 to $14.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Gil M. Labrucherie, Attorney-in-Fact 2016-01-21